Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic drug monitoring in inflammatory bowel disease
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Pharmacogenomics: Driving Personalized Medicine
Wolfgang Sadée, Daqing Wang, Katherine E. Hartmann, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 4, pp. 789-814
Open Access | Times Cited: 76
Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease.
Sean Fine, K. Papamichael, Adam S. Cheifetz
PubMed (2019) Vol. 15, Iss. 12, pp. 656-665
Closed Access | Times Cited: 94
Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
Sara Lega, Becky L. Phan, Casey J. Rosenthal, et al.
Inflammatory Bowel Diseases (2018) Vol. 25, Iss. 1, pp. 134-141
Closed Access | Times Cited: 79
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis
Konstantinos Papamichael, Niels Vande Casteele, Jenny Jeyarajah, et al.
The American Journal of Gastroenterology (2020) Vol. 116, Iss. 5, pp. 1007-1014
Open Access | Times Cited: 50
Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies
Akshita Bhalla, Aakash Shahi, Madhurima Maity, et al.
Cureus (2025)
Open Access
Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real‐World Data
David Sealey, Kai Fai Ho, Z C Zhou, et al.
Canadian Journal of Gastroenterology and Hepatology (2025) Vol. 2025, Iss. 1
Open Access
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn’s disease
Yang Tian, Jing Feng, Ruchen Yao, et al.
Insights into Imaging (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease
Laurie B. Grossberg, Konstantinos Papamichael, Joseph D. Feuerstein, et al.
Inflammatory Bowel Diseases (2017) Vol. 24, Iss. 1, pp. 191-197
Open Access | Times Cited: 42
Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
J M Huguet, V. García, Lidia Martí, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2130-2130
Open Access | Times Cited: 20
Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review
Monica State, Lucian Negreanu
Biomedicines (2023) Vol. 11, Iss. 2, pp. 544-544
Open Access | Times Cited: 11
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Epithelial NAD+ depletion drives mitochondrial dysfunction and contributes to intestinal inflammation
Elizabeth Novak, Erin C. Crawford, Heather Mentrup, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 4, pp. 371-379
Open Access | Times Cited: 27
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
Antonello Di Paolo, Giacomo Luci
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 25
Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Hye Kyung Hyun, Hyun‐Soo Zhang, Jongwook Yu, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 16
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine (2022) Vol. 37, Iss. 5, pp. 895-905
Open Access | Times Cited: 16
Management of refractory inflammatory bowel disease
M Gergely, Eric Prado, Parakkal Deepak
Current Opinion in Gastroenterology (2022) Vol. 38, Iss. 4, pp. 347-357
Closed Access | Times Cited: 15
The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study
Cynthia H. Seow, John K. Marshall, Erin Stewart, et al.
Journal of the Canadian Association of Gastroenterology (2024) Vol. 7, Iss. 4, pp. 290-298
Open Access | Times Cited: 2
Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
Farah Albader, Petra A. Golovics, Lóránt Gönczi, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 37, pp. 6231-6247
Open Access | Times Cited: 19
Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
Camilla de Almeida Martins, Karoline Soares Garcia, Natália Sousa Freitas Queiroz
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 13
Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2452-2452
Open Access | Times Cited: 6
Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease
Antonius T. Otten, Hedwig H van der Meulen, Maurice Steenhuis, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 3, pp. 325-335
Open Access | Times Cited: 6
Obesity, a challenge in the management of inflammatory bowel diseases
Mohsen Rajabnia, Shideh Moftakhari Hajimirzaei, Mohammad Reza Hatamnejad, et al.
Immunologic Research (2022) Vol. 70, Iss. 6, pp. 742-751
Closed Access | Times Cited: 9
Antibiotics influence the risk of anti-drug antibody formation during anti-TNF therapy in Chinese inflammatory bowel disease patients
Meng Sun, Jingyi Ju, Hongzhen Xu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top